Today, Celgene Corp. (CELG) Given Outperform Rating at BMO Capital Markets

Today, Celgene Corp. (CELG) Given Outperform Rating at BMO Capital Markets

BMO Capital Markets restated their outperform rating on shares of Celgene Corp. (NASDAQ:CELG) in a report issued on Monday. They currently have a $141.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on CELG. JMP Securities reissued a buy rating and issued a $152.00 price objective on shares of Celgene Corp. in a report on Thursday, June 23rd. Vetr lowered Celgene Corp. from a strong-buy rating to a buy rating and set a $111.27 price objective on the stock. in a report on Thursday, June 23rd. Canaccord Genuity reissued a buy rating and issued a $156.00 price objective on shares of Celgene Corp. in a report on Monday, June 27th. Jefferies Group reissued a buy rating and issued a $140.00 price objective on shares of Celgene Corp. in a report on Wednesday, June 29th. Finally, Morgan Stanley reaffirmed a hold rating on shares of Celgene Corp. in a report on Thursday, June 30th. Three equities research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the company’s stock. Celgene Corp. presently has a consensus rating of Buy and a consensus price target of $136.46.

Celgene Corp. (NASDAQ:CELG) traded up 0.68% on Monday, reaching $100.32. The company had a trading volume of 228,727 shares. The stock has a market capitalization of $77.76 billion, a P/E ratio of 42.40 and a beta of 1.49. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $128.39. The stock’s 50 day moving average is $105.50 and its 200-day moving average is $105.57.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.05. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The company’s revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.23 earnings per share. On average, equities analysts predict that Celgene Corp. will post $5.71 EPS for the current fiscal year.

In other news, Director Michael A. Friedman sold 56,116 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $103.66, for a total value of $5,816,984.56. Following the completion of the sale, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $5,183,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $106.44, for a total value of $1,033,532.40. Following the completion of the sale, the director now directly owns 72,142 shares of the company’s stock, valued at $7,678,794.48. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of CELG. Agur Provident & Training Funds Management Ltd. purchased a new stake in Celgene Corp. during the first quarter valued at $926,000. Wrapmanager Inc. boosted its position in shares of Celgene Corp. by 29.9% in the first quarter. Wrapmanager Inc. now owns 2,378 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 547 shares during the period. NF Trinity Capital Hong Kong Ltd boosted its position in shares of Celgene Corp. by 486.9% in the first quarter. NF Trinity Capital Hong Kong Ltd now owns 146,717 shares of the biopharmaceutical company’s stock valued at $14,685,000 after buying an additional 121,717 shares during the period. Woodstock Corp boosted its position in shares of Celgene Corp. by 2.0% in the first quarter. Woodstock Corp now owns 105,041 shares of the biopharmaceutical company’s stock valued at $10,514,000 after buying an additional 2,040 shares during the period. Finally, Peapack Gladstone Financial Corp boosted its position in shares of Celgene Corp. by 1.9% in the first quarter. Peapack Gladstone Financial Corp now owns 57,230 shares of the biopharmaceutical company’s stock valued at $5,728,000 after buying an additional 1,050 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

About Celgene Corp.

Related posts

Leave a Comment